1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Introduction
2.2. Define: Research Objective
2.3. Determine: Research Design
2.4. Prepare: Research Instrument
2.5. Collect: Data Source
2.6. Analyze: Data Interpretation
2.7. Formulate: Data Verification
2.8. Publish: Research Report
2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19

6. Gastric Cancer Drugs Market, by Route of Administration
6.1. Introduction
6.2. Oral
6.3. Parenteral

7. Gastric Cancer Drugs Market, by Lines of Chemotherapy
7.1. Introduction
7.2. First-line Chemotherapy
7.3. Second-line Chemotherapy

8. Gastric Cancer Drugs Market, by Molecule Type
8.1. Introduction
8.2. Biologics
8.3. Small Molecules

9. California Gastric Cancer Drugs Market

10. Florida Gastric Cancer Drugs Market

11. Illinois Gastric Cancer Drugs Market

12. New York Gastric Cancer Drugs Market

13. Ohio Gastric Cancer Drugs Market

14. Pennsylvania Gastric Cancer Drugs Market

15. Texas Gastric Cancer Drugs Market

16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion

17. Company Usability Profiles
17.1. Amgen Inc.
17.2. Arog Pharmaceuticals, Inc.
17.3. ASLAN Pharmaceuticals
17.4. AstraZeneca plc
17.5. Bayer AG
17.6. Bristol Myers Squibb company
17.7. Celltrion inc.
17.8. Eli Lilly and Company
17.9. F. Hoffmann-La Roche AG
17.10. Ipsen Biopharmaceuticals, Inc.
17.11. Merck & Co., Inc.
17.12. Novartis International AG
17.13. Pfizer Inc.
17.14. SELLAS Life Sciences Group, Inc.
17.15. Taiho Oncology, Inc.
17.16. Takeda Pharmaceutical Company Limited

18. Appendix
18.1. Discussion Guide
18.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES GASTRIC CANCER DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES GASTRIC CANCER DRUGS MARKET: MARKET DYNAMICS
FIGURE 3. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2027 (%)
FIGURE 4. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2020 VS 2027 (USD MILLION)
FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2027
FIGURE 6. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, 2018-2027 (USD MILLION)
FIGURE 7. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 8. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY PARENTERAL, 2018-2027 (USD MILLION)
FIGURE 9. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 10. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2020 VS 2027 (%)
FIGURE 11. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2020 VS 2027 (USD MILLION)
FIGURE 12. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2027
FIGURE 13. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST-LINE CHEMOTHERAPY, 2018-2027 (USD MILLION)
FIGURE 14. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST-LINE CHEMOTHERAPY, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 15. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND-LINE CHEMOTHERAPY, 2018-2027 (USD MILLION)
FIGURE 16. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND-LINE CHEMOTHERAPY, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 17. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2020 VS 2027 (%)
FIGURE 18. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2020 VS 2027 (USD MILLION)
FIGURE 19. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2027
FIGURE 20. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2027 (USD MILLION)
FIGURE 21. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 22. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2027 (USD MILLION)
FIGURE 23. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY SMALL MOLECULES, BY STATE, 2020 VS 2027 (USD MILLION)
FIGURE 24. UNITED STATES GASTRIC CANCER DRUGS MARKET: FPNV POSITIONING MATRIX
FIGURE 25. UNITED STATES GASTRIC CANCER DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 26. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES GASTRIC CANCER DRUGS MARKET, BY TYPE

List of Tables

TABLE 1. UNITED STATES GASTRIC CANCER DRUGS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)
TABLE 4. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ORAL, BY STATE, 2018-2027 (USD MILLION)
TABLE 5. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY PARENTERAL, BY STATE, 2018-2027 (USD MILLION)
TABLE 6. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY LINES OF CHEMOTHERAPY, 2018-2027 (USD MILLION)
TABLE 7. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY FIRST-LINE CHEMOTHERAPY, BY STATE, 2018-2027 (USD MILLION)
TABLE 8. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY SECOND-LINE CHEMOTHERAPY, BY STATE, 2018-2027 (USD MILLION)
TABLE 9. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2027 (USD MILLION)
TABLE 10. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY BIOLOGICS, BY STATE, 2018-2027 (USD MILLION)
TABLE 11. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY SMALL MOLECULES, BY STATE, 2018-2027 (USD MILLION)
TABLE 12. UNITED STATES GASTRIC CANCER DRUGS MARKET: SCORES
TABLE 13. UNITED STATES GASTRIC CANCER DRUGS MARKET: BUSINESS STRATEGY
TABLE 14. UNITED STATES GASTRIC CANCER DRUGS MARKET: PRODUCT SATISFACTION
TABLE 15. UNITED STATES GASTRIC CANCER DRUGS MARKET: RANKING
TABLE 16. UNITED STATES GASTRIC CANCER DRUGS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 17. UNITED STATES GASTRIC CANCER DRUGS MARKET: MERGER & ACQUISITION
TABLE 18. UNITED STATES GASTRIC CANCER DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 19. UNITED STATES GASTRIC CANCER DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 20. UNITED STATES GASTRIC CANCER DRUGS MARKET: INVESTMENT & FUNDING
TABLE 21. UNITED STATES GASTRIC CANCER DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 22. UNITED STATES GASTRIC CANCER DRUGS MARKET: LICENSE & PRICING

Companies Mentioned

Amgen Inc.
Arog Pharmaceuticals, Inc.
ASLAN Pharmaceuticals
AstraZeneca plc
Bayer AG
Bristol Myers Squibb company
Celltrion inc.
Eli Lilly and Company
F. Hoffmann-La Roche AG
Ipsen Biopharmaceuticals, Inc.
Merck & Co., Inc.
Novartis International AG
Pfizer Inc.
SELLAS Life Sciences Group, Inc.
Taiho Oncology, Inc.
Takeda Pharmaceutical Company Limited